Shots: The P-III MYSTIC Trial involves assessing of Imfinzi (durvalumab) as a monothx or Imfinzi plus tremelimumab vs SoC Pt-based CT in patients with EGFR and anaplastic lymphoma kinase (ALK) wild-type, locally-advanced or metastatic Stage IV NSCLC in 167 centers across 17 countries MYSTIC Trial included 1EPs as PFS for combination and OS for monothx […]Read More
Tags : Mystic Trial
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US